Drug firm Lupin today said it has settled its patent dispute with Ireland-based Warner Chilcott regarding two oral contraceptives Loestrin 24 Fe and Femcon Fe.
The settlement agreement has been entered with Warner Chilcott plc and its subsidiary Warner Chilcott Company LLC, Lupin said in statement.
Under the settlement, Lupin has agreed not to sell a generic version of Loestrin 24 Fe before the patent expiry on July 2014.
In addition, Lupin has been granted a non-exclusive license to market in the US, generic Femcon Fe, which would be supplied by Warner Chilcott, it added.
The selling of the drug in the US will, however, be only after the expiry of 180 days of marketing exclusivity rights that Israel's Teva Pharmaceutical Industries holds or January 1, 2013, whichever earlier.
In 2009, Lupin had filed for approval from the US Food and Drug Administration for the generic versions of the oral contraceptives.
Lupin also said it has also been granted rights to sell in the US a generic version of Asacol 400 mg tablets, used to treat ulcerative colitis, which will be supplied by Warner Chilcott only if a generic version of the same is launched by a third party in the American market.
The final agreement remains subject to certain conditions specified in the settlement agreement including court's ordering the stipulations of dismissal, it added.
Shares of Lupin were trading at Rs 430.10 on the BSE in the late afternoon trade, down 0.15 per cent from its previous close.